BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 10, 2026
Home » Authors » Brian Orelli

Articles by Brian Orelli

Russia makes push to develop biotech sector with start-ups

June 30, 2014
By Brian Orelli
SAN DIEGO – The Russian government is making a push to diversify its economy away from oil and gas into technology-based industries, including biomedical research.
Read More

Partnerships key for up-and-coming African biotechs

June 27, 2014
By Brian Orelli
SAN DIEGO – At the BIO International Convention, BIO Ventures for Global Health (BVGH) announced a partnership with the National Universities Commission (NUC) of Nigeria to place Nigerian academics at pharmaceutical and biotech companies.
Read More

Accessing biodefense funding, experts to share experiences

June 16, 2014
By Brian Orelli
In a Thursday session at BIO 2014 next week, attendees will get a lesson from a panel of experts on how to get a piece of the government funding available for companies developing medical countermeasures (MCMs).
Read More

Accessing biodefense funding, experts to share experiences

June 16, 2014
By Brian Orelli
In a Thursday session at BIO 2014 next week, attendees will get a lesson from a panel of experts on how to get a piece of the government funding available for companies developing medical countermeasures (MCMs).
Read More

Want data from the FDA? There's an app for that

June 9, 2014
By Brian Orelli
Last week, the FDA launched OpenFDA, an initiative to make public FDA data available through an application program interface (API), which allows mobile phone app and web developers to access the data directly and present them on websites and mobile apps.
Read More

Reproducibility of experiments key for progress, investments

May 27, 2014
By Brian Orelli
It's hard to build up scientific knowledge and search for targeted drugs if the foundation isn't solid. But that's exactly what companies have found over the years.
Read More

High priced cancer drugs not translating into lofty revenue

May 12, 2014
By Brian Orelli
The average cost per month for a branded oncology drug treatment in the U.S. is about $10,000, around double where it was a decade ago, according to a new report by IMS Institute for Healthcare Informatics.
Read More

Specialty pharma sector hot on M&A, tax savings, products

May 5, 2014
By Brian Orelli
One sure sign that specialty pharma sector M&A is on fire: companies in the process of closing acquisition deals are acquiring companies while they wait for antitrust regulators to sign off on their deal.
Read More

Small firms targeting therapies at the complement system

April 28, 2014
By Brian Orelli
The complement system is designed to kill pathogens through a signal cascade that results in cell lysis, removal of the pathogens through phagocytosis, and alerting other immune system cells to help with infections. Signals come from three different pathways – classical, lectin and alternative – culminating at the C3 protein of the cascade.
Read More

Small firms targeting therapies at the complement system

April 21, 2014
By Brian Orelli
The complement system is designed to kill pathogens through a signal cascade that results in cell lysis, removal of the pathogens through phagocytosis, and alerting other immune system cells to help with infections. Signals come from three different pathways – classical, lectin and alternative – culminating at the C3 protein of the cascade.
Read More
Previous 1 2 … 38 39 40 41 42 43 44 45 46 … 59 60 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 9, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • 3D illustration of antibodies

    Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

    BioWorld Science
    Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing